GILEAD SCIENCES, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
GILEAD SCIENCES, INC. (GILD) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss of $0 as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss · last filed 2025-08-07
- 2025-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $0.00.
- 2023-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $8.00M.
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $14.00M.
- 2023-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $16.00M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss |
|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2023-12-31 | $8.00M 10-K · filed 2025-02-28 |
| 2023-09-30 | $14.00M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $16.00M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $18.00M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $12.00M 10-K · filed 2024-02-23 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-22 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 |
| 2019-09-30 | $1.00M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $5.00M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $22.00M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $52.00M 10-K · filed 2020-02-25 |
| 2018-09-30 | $64.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $83.00M 10-Q · filed 2018-08-06 |
| 2017-12-31 | $80.00M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |